Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Published version of a preprint
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. Significance: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. Cancer Discov; 6(12); 1382–99. ©2016 AACR. See related commentary by Melero et al., p. 1312. This article is highlighted in the In This Issue feature, p. 1293
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Data from a landmark study using an orthotopic model of breast cancer showed that neoadjuvant ICIs might outperform adjuvant ICIs106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
In the citing paper
“Delivering ICIs after surgery enabled T cell expansion, and yielded the best antitumour activity while also decreasing toxicity106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 101–200 of 930
The adjuvant treatment of kidney cancer: a multidisciplinary outlook
Porta, C., Cosmai, L., Leibovich, B. C., Powles, T. B., Gallieni, M. A., & Bex, A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0131-x · Cited by 102
Jia, X., Xu, H., Geng, L., Jiao, M., Wang, W., Jiang, L., & Guo, H. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.001 · Cited by 110
Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
Wirth, T. C., & Kühnel, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01848 · Cited by 98
The immune landscape of common CNS malignancies: implications for immunotherapy
Ott, M., Prins, R. M., & Heimberger, A. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00518-9 · Cited by 95
The role of NK cells and CD39 in the immunological control of tumor metastases
Zhang, H., Vijayan, D., Li, X.-Y., Robson, S. C., Geetha, N., Teng, M. W. L., & Smyth, M. J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593809 · Cited by 95
“2 mammary carcinoma (CD73 CD39, Supplementary Figure 2(b)) model where neoadjuvant therapy is given prior to surgical resection of the primary tumor.(3) All mice untreated or treated with PBS typically die of distant metastasis to the lung, bones and other organs within 25 to 40 days of surgery (Figure 5(d)).”
BackgroundMethodInfluentialSelf-citationChuntova, P., Chow, F. E., Watchmaker, P. B., Galvez, M., Heimberger, A. B., Newell, E. W., Diaz, A. A., DePinho, R. A., Li, M. O., Wherry, E. J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa277 · Cited by 96
Bae, J., Liu, L., Moore, C., Hsu, E. J., Zhang, A., Ren, Z., Sun, Z., Wang, X., Zhu, J., Shen, J., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-01024-5 · Cited by 94
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
Reijers, I. L. M., Rao, D., Versluis, J. M., Menzies, A. M., Dimitriadis, P., Wouters, M. W. J. M., Spillane, A. J., Klop, W. M. C., Broeks, A., Bosch, L. J. W., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221952 · Cited by 91
The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer
Nair, S. S., Weil, R., Dovey, Z. S., Davis, A., & Tewari, A. K. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.10.005 · Cited by 98
Friedman, J., Moore, E. C., Zolkind, P., Robbins, Y., Clavijo, P. E., Sun, L., Greene, S., Morisada, M. V., Mydlarz, W. K., Schmitt, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2209 · Cited by 88
Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder
Rouanne, M., Bajorin, D. F., Hannan, R., Galsky, M. D., Williams, S. B., Necchi, A., Sharma, P., & Powles, T. B. (2020) · European Urology Oncology · doi:10.1016/j.euo.2020.06.009 · Cited by 93
Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
Brockwell, N. K., Owen, K. L., Zanker, D. J., Spurling, A., Rautela, J., Duivenvoorden, H. M., Baschuk, N., Caramia, F., Loi, S., Darcy, P. K., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0150 · Cited by 92
Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma
Maxwell, R., Jackson, C. M., & Lim, M. K. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0492-y · Cited by 94
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
Lü, Z., Peng, Z., Liu, C. X., Wang, Z., Wang, Y., Jiao, X., Li, J., & Shen, L. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100041 · Cited by 91
“ICI as a neoadjuvant therapy could result in a more effective prevention of tumor relapse than adjuvant therapy, and was recently explored in preclinical mouse models.(123) The advantages of neoadjuvant immunotherapy can be attributed to several aspects.”
BackgroundCD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
Melero, I., Sanmamed, M. F., Glez‐Vaz, J., Luri‐Rey, C., Wang, J., & Chen, L. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1029 · Cited by 90
He, B., Johansson, A., Backhouse, J., Li, J., Lee, G., Hamzah, J., & Ganß, R. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.013 · Cited by 85
Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma
Deng, C., Xu, Y., Fu, J., Zhu, X., Chen, H., Xu, H., Wang, G., Song, Y., Song, G., Lu, J., et al. (2020) · Cancer Science · doi:10.1111/cas.14398 · Cited by 84
Control of Metastases via Myeloid CD39 and NK Cell Effector Function
Yan, J., Li, X.-Y., Aguilera, A. R., Xiao, C., Jacoberger-Foissac, C., Nowlan, B., Robson, S. C., Beers, C., Moesta, A. K., Geetha, N., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0749 · Cited by 85
Self-citationMota Reyes, C., Teller, S., Muckenhuber, A., Konukiewitz, B., Safak, O., Weichert, W., Friess, H., Ceyhan, G. O., & Demir, I. E. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1864 · Cited by 80
Román, A. R., de la Cruz, J. L. C.-C., Macía, I., Campuzano, I. E., Almánzar, S. F., Roel, M. D., Muñoz, C. G., Fontán, E. M. G., Trueba, I. M., Laura, R. V., et al. (2021) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezab007 · Cited by 83
The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma
Ernst, M. K., & Giubellino, A. (2022) · Biomedicines · doi:10.3390/biomedicines10040822 · Cited by 90
Liu, S.-L., Li, X. N., Yang, J.-H., Wen, D., Guo, S., Liu, L., Li, Y., Luo, M.-J., Xie, S., Liang, Y.-J., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00504-7 · Cited by 85
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma
Flippot, R., Escudier, B. J., & Albiges, L. K. (2018) · Drugs · doi:10.1007/s40265-018-0970-y · Cited by 81
“Several studies are ongoing using neoadjuvant immune checkpoint inhibitors, with the rationale that initiating such treatment before removing the tumor might elicit a more important anti-tumor response, due to the presence of more tumor antigens [42].”
BackgroundEO771, is it a well‐characterized cell line for mouse mammary cancer model? Limit and uncertainty
Naour, A. L., Rossary, A., & Vasson, M. (2020) · Cancer Medicine · doi:10.1002/cam4.3295 · Cited by 85
Combination immunotherapy strategies for glioblastoma
Chan, H. Y., Choi, J. H., Jackson, C., & Lim, M. K. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03481-0 · Cited by 79
Qu, X., Zhou, D. F., Lu, J., Qin, D., Zhou, J. M., & Liu, H.-J. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.12.010 · Cited by 90
Zhou, Q. H., Pan, Y., Yang, X., Zhao, Y., Han, G., Pang, Q., Zhang, Z., Wang, Q., Yao, J., Wang, H., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.024 · Cited by 80
Ooki, A., Osumi, H., Yoshino, K., & Yamaguchi, K. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01523-4 · Cited by 81
“Several preclinical studies have shown that neoadjuvant PD-1/PD-L1 blockade disrupts immunodominance and facilitates the early establishment of immunological memory following primary tumor resection, a phenomenon not observed in the adjuvant setting [204, 205].”
Background2018 Nobel Prize in physiology or medicine
Smyth, M. J., & Teng, M. W. L. (2018) · Clinical & Translational Immunology · doi:10.1002/cti2.1041 · Cited by 90
Self-citationThe right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy
Kwon, M., Jung, H., Nam, G., & Kim, I.-S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.009 · Cited by 78
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Davar, D., Morrison, R. M., Dzutsev, A., Karunamurthy, A. D., Chauvin, J.-M., Amatore, F., Deutsch, J. S., das Neves, R. X., Rodrigues, R. R., McCulloch, J. A., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.10.007 · Cited by 80
Eichhorn, F., Klotz, L. V., Bischoff, H. G., Thomas, M., Lasitschka, F., Winter, H., Hoffmann, H., & Eichhorn, M. (2019) · BMC Cancer · doi:10.1186/s12885-019-5624-2 · Cited by 76
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
Ingels, A., Campi, R., Capitanio, U., Amparore, D., Bertolo, R. G., Carbonara, U., Erdem, S., Kara, Ö., Klatte, T., KRIEGMAIR, M. C., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00592-3 · Cited by 82
Zhou, Y., Li, A., Yu, H., Wang, Y., Zhang, X., Qiu, H., Du, W. T., Luo, L., Fu, S., Zhang, L., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.1285 · Cited by 80
Krishnamoorthy, M., Lenehan, J. G., & Vareki, S. M. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa216 · Cited by 76
“and explains the long-term protective effect of neoadjuvant immunotherapy against highly metastatic cancer cell lines (37).”
BackgroundResultInfluentialPerspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma
Pinato, D. J., Fessas, P., Sapisochin, G., & Marron, T. U. (2021) · Hepatology · doi:10.1002/hep.31697 · Cited by 74
Ignatiadis, M., Bailey, A., McArthur, H. L., El-Abed, S., de Azambuja, E., Metzger, O., Chui, S. Y., Dieterich, M., Perretti, T., Shearer-Kang, E., et al. (2025) · JAMA · doi:10.1001/jama.2024.26886 · Cited by 78
Baird, J. R., Bell, R. B., Troesch, V., Friedman, D. J., Bambina, S., Kramer, G. F., Blair, T. C., Medler, T. R., Wu, Y., Sun, Z., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1652 · Cited by 75
Brooks, J., Fleischmann-Mundt, B., Woller, N., Niemann, J., Ribback, S., Peters, K., Demir, İ. E., Armbrecht, N., Ceyhan, G. O., Manns, M. P., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2415 · Cited by 75
Self-citationFraterman, I., Reijers, I. L. M., Dimitriadis, P., Broeks, A., Gonzalez, M., Menzies, A. M., López‐Yurda, M., Kapiteijn, E., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02631-x · Cited by 75
“ICB efficacy is dependent on these immune-supportive cells, and depletion or neutralization of for example CD8 + and CD4 + cells diminishes this efficacy 25 .”
BackgroundImmune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting
Herrscher, H., & Robert, C. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000610 · Cited by 79
“Some preclinical data suggest that neoadjuvant treatment with ICI might be superior than adjuvant treatment [47].”
BackgroundBatf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy
Liu, J., Rozeman, E. A., O’Donnell, J. S., Allen, S., Fanchi, L., Smyth, M. J., Blank, C. U., & Teng, M. W. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1546068 · Cited by 70
Self-citationYamamoto, S., Kato, K., Daiko, H., Kojima, T., Hara, H., Abe, T., Tsubosa, Y., Nagashima, K., Aoki, K., Mizoguchi, Y., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0189 · Cited by 71
Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer
Kuusk, T., Albiges, L. K., Escudier, B. J., Grivas, N., Haanen, J. B. A. G., Powles, T. B., & Bex, A. (2017) · Angiogenesis · doi:10.1007/s10456-017-9550-0 · Cited by 74
“Preclinical and early clinical research suggest that there is significantly greater therapeutic efficacy of neoadjuvant immunotherapies in eradicating early occult metastases than with an adjuvant approach, following primary tumour resection [51].”
Kaseb, A. O., Vence, L., Blando, J., Yadav, S. S., Ikoma, N., Pestana, R. C., Vauthey, J. N., Allison, J. P., & Sharma, P. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0605 · Cited by 67
Rawson, R. V., Adhikari, C., Bierman, C., Lo, S., Shklovskaya, E., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Shannon, K. F., Gonzalez, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.006 · Cited by 72
Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?
Zhu, J., Lian, J., Xu, B., Pang, X., Ji, S., Zhao, Y., & Lu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1120684 · Cited by 74
“3) NR 3 (25) (enteritis, oral ulcer and hyperthyroidism) (78)”
BackgroundInfluentialDammeijer, F. F., Lau, S. P., van Eijck, C. H. J., van der Burg, S. H., & Aerts, J. G. J. V. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.011 · Cited by 75
Ou, Y., Wen, X., Johnson, C. A., Shae, D., Ayala, O. D., Webb, J. A., Lin, E. C., DeLapp, R. C., Boyd, K. L., Richmond, A. J., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b07326 · Cited by 67
Luginbuhl, A., Johnson, J. M., Harshyne, L. A., Linnenbach, A. J., Shukla, S. K., Alnemri, A. E., Kumar, G., Cognetti, D. M., Curry, J., Kotlov, N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1816 · Cited by 70
Immunotherapy Approaches for Breast Cancer Patients in 2023
Emens, L. A., & Loi, S. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041332 · Cited by 70
Fukuoka, E., Yamashita, K., Tanaka, T., Sawada, R., Sugita, Y., Arimoto, A., Fujita, M., Takiguchi, G., Matsuda, T., Oshikiri, T., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13631 · Cited by 66
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern, E. S., Solomon, B., Hui, R., Pavlakis, N., O'Byrne, K. J., & Hughes, B. G. M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002248 · Cited by 70
“28 37 85 Unanswered questions relate to the ideal timing and duration of immunotherapy administration, including Open access number of preoperative doses and scheduling with respect to surgery, predictive biomarkers to direct selection of therapy (eg, monotherapy ICI vs combination…”
Immune-based therapies in penile cancer
Joshi, V. B., Spiess, P. E., Necchi, A., Pettaway, C. A., & Chahoud, J. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00617-x · Cited by 70
Immunotherapy in non-small cell lung cancer: update and new insights
Mielgo-Rubio, X., Uribelarrea, E. A., Cortés, L. Q., & Moyano, M. S. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202101.001 · Cited by 78
Cottrell, T. R., Lotze, M. T., Ali, A., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D. E., Cope, L., Deutsch, J. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010928 · Cited by 69
“212 Moreover, immunotherapy given in earlier settings has a higher chance of efficacy than in the advanced setting where complex heterogenetic immunologic resistance mechanisms play a more prominent role.”
Experimental animal modeling for immuno-oncology
Li, Q., Feuer, G., Ouyang, X., & An, X. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.002 · Cited by 67
Current status of immunotherapy for advanced gastric cancer
Kawazoe, A., Shitara, K., Boku, N., Yoshikawa, T., & Terashima, M. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa202 · Cited by 67
Provencio, M., Calvo, V., Romero, A., Spicer, J. D., & Cruz‐Bermúdez, A. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_358995 · Cited by 65
Small molecules as theranostic agents in cancer immunology
Li, J., Valkenburgh, J. S. V., Hong, X., Conti, P. S., Zhang, X., & Chen, K. (2019) · Theranostics · doi:10.7150/thno.37218 · Cited by 66
Zhang, J., Cai, J. Q., Deng, Y., & Wang, H. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1663108 · Cited by 65
“This concept had been underpinned in preclinical study.(21) The limitations of our study include the small number of patients enrolled and the short postoperative follow-up period.”
BackgroundLiu, S., Knochelmann, H. M., Lomeli, S. H., Hong, A., Richardson, M. S., Yang, Z., Lim, R. J., Wang, Y., Dumitras, C., Krysan, K., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100411 · Cited by 67
Heras‐Murillo, I., Mañanes, D., Munné, P., Núñez, V., Herrera, J., Català-Montoro, M., Álvarez, M., del Pozo, M. Á., Melero, I., Wculek, S. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58289-1 · Cited by 65
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy
Dunn, G. P., Cloughesy, T. F., Maus, M. V., Prins, R. M., Reardon, D. A., & Sonabend, A. M. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa154 · Cited by 61
Lee, Y. J., Kim, J. Y., Jeon, S. H., Nam, H., Jung, J. H., Jeon, M., Kim, E.-S., Bae, S. J., Ahn, J., Yoo, T.-K., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn8390 · Cited by 66
Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future
Singal, A. G., Yarchoan, M. M., Yopp, A. C., Sapisochín, G., Pinato, D. J., & Pillai, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000430 · Cited by 63
“[50] 51 – 53] It is posited that the presence of an active and measurable tumor might lead to improved neoantigen recognition, DC priming, and ultimately immunological clearance of active and micrometastatic disease.”
BackgroundRodríguez, J., Álvarez, E. C., Perez‐Gracia, J. L., Rodríguez, I., Viúdez, A., Alfaro, C., Oñate, C., Pérez, G., Rotellar, F., Inogés, S., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0405-z · Cited by 64
Considering adjuvant therapy for stage II melanoma
Poklepovic, A. S., & Luke, J. J. (2019) · Cancer · doi:10.1002/cncr.32585 · Cited by 62
“Some preclinical models suggested that neoadjuvant therapy with clinically detectable volumes of disease would be required to induce long-term disease control.(20)”
BackgroundKos, K., Aslam, M. A., van de Ven, R., Wellenstein, M. D., Pieters, W., van Weverwijk, A., Duits, D. E. M., van Pul, K., Hau, C., Vrijland, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110447 · Cited by 60
The Multifaceted Role of Regulatory T Cells in Breast Cancer
Kos, K., & de Visser, K. E. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042920-104912 · Cited by 58
Immunotherapy in surgically resectable non-small cell lung cancer
Owen, D. H., & Chaft, J. E. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.93 · Cited by 59
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies
Keung, E. Z.-Y., Ukponmwan, E. U., Cogdill, A. P., & Wargo, J. A. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6379-8 · Cited by 59
“NCT03127007 Safety and efficacy of atezolizumab combined with preoperative radiochemotherapy in localized rectal cancer (R-IMMUNE) 1/2 Not yet recruiting (54) This study aims to determine the safety and tolerance of administration at a fixed dosing of 1200 mg/3 weeks, concomitantly to the standard preoperative radioch…”
Perioperative Immune Checkpoint Inhibition in Early-Stage Non–Small Cell Lung Cancer: A Review
Desai, A. P., Adashek, J. J., Reuss, J. E., West, H., & Mansfield, A. S. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5389 · Cited by 58
Kaptein, P., Jacoberger-Foissac, C., Dimitriadis, P., Voabil, P., de Bruijn, M., Brokamp, S., Reijers, I., Versluis, J., Nallan, G., Triscott, H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9779 · Cited by 52
Self-citationNeoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease
Mittendorf, E. A., Burgers, F. H., Haanen, J. B. A. G., & Cascone, T. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349411 · Cited by 63
Zhao, J., Zhao, L., Guo, W., Wang, S., Tao, X., Li, L., Mao, Y., Tan, F., Gao, Y., Wu, N., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.02.019 · Cited by 60
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
Singh, T., Hassanabad, M. F., & Hassanabad, A. F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188636 · Cited by 62
Neoadjuvant immunotherapy for resectable esophageal cancer: A review
Li, Q., Liu, T., & Ding, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1051841 · Cited by 57
Adjuvant and neoadjuvant therapies for hepatocellular carcinoma
Vogel, A., Grant, R. C., Meyer, T., Sapisochín, G., O'Kane, G. M., & Saborowski, A. L. (2023) · Hepatology · doi:10.1097/hep.0000000000000726 · Cited by 60
Li, Z., Liu, J., Zhang, B., Yue, J., Shi, X., Cui, K., Liu, Z., Chang, Z., Sun, Z., Li, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47420-3 · Cited by 60
Self-citationCheckpoint immunotherapy in head and neck cancers
Zolkind, P., & Uppaluri, R. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9694-9 · Cited by 51
“A preclinical model of metastatic breast cancer found that neoadjuvant immunotherapy with regulatory T cell (Treg) depletion reduced recurrence, metastases, and improved overall survival—19/20 mice with long-term survival (> 250 days) in the neoadjuvant cohort compared to 5/20 mice surviving in the adjuvant treatment-…”
Integration of radiation and immunotherapy in breast cancer - Treatment implications
Ye, J. C., & Formenti, S. C. (2018) · The Breast · doi:10.1016/j.breast.2017.12.005 · Cited by 58
Kavun, A., Veselovsky, E., Lebedeva, A., Belova, E., Kuznetsova, O. A., Yakushina, V. D., Grigoreva, T. V., Mileyko, V., Fedyanin, M. Y., & Ivanov, M. V. (2023) · Cancers · doi:10.3390/cancers15082288 · Cited by 62
Liu, S., Dong, S., Yang, X., Liao, R.-Q., Jiang, B., Wang, Q., Ben, X., Qiao, G., Lin, J., Yan, H., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01700-4 · Cited by 57
The danger theory of immunity revisited
Kroemer, G., Montégut, L., Kepp, O., & Zitvogel, L. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01102-9 · Cited by 58
“Moreover, the greater therapeutic efficacy of neoadjuvant , as opposed to adjuvant, chemotherapies and immunotherapies against cancers 22,27–29 , supports the view that whole tissue rather than minimal residual disease owing to isolated transformed cells should be targeted for the induction of…”
Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma
Hanna, G. J., Adkins, D. R., Zolkind, P., & Uppaluri, R. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.08.008 · Cited by 56
“Liu and colleagues recently utilized two murine models of metastatic breast cancer to demonstrate the early efficacy of neoadjuvant immunotherapy (Treg depletion, anti-PD-1 and anti-CD-137 therapies) compared with an adjuvant strategy [26].”
BackgroundCurrent Panorama and Challenges for Neoadjuvant Cancer Immunotherapy
Benítez, J. C., Remón, J., & Besse, B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3255 · Cited by 60
Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non–Small-Cell Lung Cancer
Passaro, A., Attili, I., & de Marinis, F. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00873 · Cited by 58
Aguilera, A. R., Lutzky, V. P., Mittal, D., Li, X.-Y., Stannard, K. A., Takeda, K., Bernhardt, G., Teng, M. W. L., Dougall, W. C., & Smyth, M. J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424677 · Cited by 55
Self-citationImmunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
Lo, J. H.-J., Agarwal, R., Goff, L. W., & Heumann, T. R. (2023) · Cancers · doi:10.3390/cancers15133312 · Cited by 56
Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
Trojaniello, C., Luke, J. J., & Ascierto, P. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670726 · Cited by 58
“The primary site of the tumor can be used as a spring of antigens for the spread and activation of tumor-specific T cells and to control micro-metastases (32); however, optimal regimens have not been defined (33).”
BackgroundImmunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
Agostinetto, E., Montemurro, F., Puglisi, F., Criscitiello, C., Bianchini, G., Mastro, L. D., Introna, M., Tondini, C. A., Santoro, A., & Zambelli, A. (2022) · Cancers · doi:10.3390/cancers14092136 · Cited by 58
Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions
Ser, M. H., Webb, M., Sener, U. T., & Campian, J. L. (2024) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-23-34 · Cited by 56
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
Albrecht, L. J., Livingstone, E., Zimmer, L., & Schadendorf, D. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01406-4 · Cited by 52
The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments
Rayson, V., Harris, M. A., Savas, P. S., Hun, M. L., Virassamy, B., Salgado, R., & Loi, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.02.008 · Cited by 54
Complex neural-immune interactions shape glioma immunotherapy
Song, K.-W., Lim, M. K., & Monje, M. (2025) · Immunity · doi:10.1016/j.immuni.2025.04.017 · Cited by 51
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
Awada, G., Cascone, T., van der Heijden, M. S., Blank, C. U., Kok, M., & Chalabi, M. (2025) · Nature Cancer · doi:10.1038/s43018-025-00990-7 · Cited by 54
“…ICIs, when the tumor and draining regional LNs are still in place, could result in higher levels of antigen presentation, priming and expansion of multiple T cell clones and eventually in a more effective and durable immune response against the primary tumor and micrometastases 31,32,37 (Fig.”
Guo, W., Wang, Y., Yang, M., Wang, Z., Wang, Y., Chaurasia, S., Wu, Z., Zhang, M., Yadav, G. S., Rathod, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb3555 · Cited by 53
“2 mouse model, consistent with a previous study ( 47 ), anti–PD-1 antibody treatment delayed 4T1.”
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Lucas, M. W., Versluis, J. M., Rozeman, E. A., & Blank, C. U. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00760-3 · Cited by 50
Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy
Melero, I., Berraondo, P., Rodriguez-Ruiz, M. E., & Perez‐Gracia, J. L. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1109 · Cited by 49
Metadata
- Authors
- Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., & Teng, M. W. L.
- Affiliations
- The University of Queensland (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Juntendo University (JP)
- 1Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
- Corresponding author
- Teng, Michele W.L.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2016-12-01
- Volume
- 6
- Issue
- 12
- Pages
- 1382-1399
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2521503673
- Cited by
- 894
- References
- 55
- Citations by year
- 2026: 86 · 2025: 91 · 2024: 135 · 2023: 112 · 2022: 113 · 2021: 112 · 2020: 101 · 2019: 65 · 2018: 50 · 2017: 23 · 2016: 1
- FWCI
- 24.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (15K14410)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- neoadjuvant immunotherapy, adjuvant immunotherapy, metastatic breast cancer, primary tumor resection, tumor-specific immunity, CD8+ T cells, predictive biomarkers
- MeSH terms
- Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Immunotherapy, Neoplasm Metastasis, Treatment Outcome, Chemotherapy, Adjuvant, CD8-Positive T-Lymphocytes, Neoadjuvant Therapy, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.